Literature DB >> 24861862

Impact of HLA diversity on donor selection in organ and stem cell transplantation.

Jean-Marie Tiercy1, Frans Claas.   

Abstract

The human major histocompatibility complex is a multigene system encoding polymorphic human leucocyte antigens (HLA) that present peptides derived from pathogens to the immune system. The high diversity of HLA alleles and haplotypes in the worldwide populations represents a major barrier to organ and allogeneic hematopoietic stem cell transplantation, because HLA incompatibilities are efficiently recognized by T and B lymphocytes. In organ transplantation, pre-transplant anti-HLA antibodies need to be taken into account for organ allocation. Although HLA-incompatible transplants can be performed thanks to immunosuppressive drugs, the de novo production of anti-HLA antibodies still represents a major cause of graft failure. The HLAMatchmaker computer algorithm determines the immunogenicity of HLA mismatches and allows to define HLA antigens that will not induce an antibody response. Because of the much higher stringency of HLA compatibility criteria in stem cell transplantation, the best donor is a HLA genotypically identical sibling. However, more than 50% of the transplants are now performed with hematopoietic stem cells from volunteer donors selected from the international registry. The development of European national registries covering populations with different HLA haplotype frequencies is essential for optimizing donor search algorithms and providing the best chance for European patients to find a fully compatible donor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24861862     DOI: 10.1159/000358798

Source DB:  PubMed          Journal:  Hum Hered        ISSN: 0001-5652            Impact factor:   0.444


  7 in total

1.  The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Authors:  N Or-Geva; Y Reisner
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 2.  Targeting Innate-Like T Cells in Tuberculosis.

Authors:  Shouxiong Huang
Journal:  Front Immunol       Date:  2016-12-21       Impact factor: 7.561

Review 3.  Generalists and Specialists: A New View of How MHC Class I Molecules Fight Infectious Pathogens.

Authors:  Jim Kaufman
Journal:  Trends Immunol       Date:  2018-01-31       Impact factor: 16.687

Review 4.  Current and future alternative therapies for beta-thalassemia major.

Authors:  Edouard de Dreuzy; Kanit Bhukhai; Philippe Leboulch; Emmanuel Payen
Journal:  Biomed J       Date:  2016-04-06       Impact factor: 4.910

5.  Genetic correction of haemoglobin E in an immortalised haemoglobin E/beta-thalassaemia cell line using the CRISPR/Cas9 system.

Authors:  Kongtana Trakarnsanga; Nontaphat Thongsin; Chanatip Metheetrairut; Chartsiam Tipgomut; Saiphon Poldee; Methichit Wattanapanitch
Journal:  Sci Rep       Date:  2022-09-16       Impact factor: 4.996

6.  HLA Polymorphisms and Haplotype Diversity in Transylvania, Romania.

Authors:  Mihaela L Vică; Horea V Matei; Cosmina I Bondor; Gheorghe Z Nicula; Costel V Siserman; Luminița Loga; Lucia Dican
Journal:  J Immunol Res       Date:  2019-12-30       Impact factor: 4.818

7.  How Ancestry Influences the Chances of Finding Unrelated Donors: An Investigation in Admixed Brazilians.

Authors:  Kelly Nunes; Vitor R C Aguiar; Márcio Silva; Alexandre C Sena; Danielli C M de Oliveira; Carla L Dinardo; Fernanda S G Kehdy; Eduardo Tarazona-Santos; Vanderson G Rocha; Anna Barbara F Carneiro-Proietti; Paula Loureiro; Miriam V Flor-Park; Claudia Maximo; Shannon Kelly; Brian Custer; Bruce S Weir; Ester C Sabino; Luís Cristóvão Porto; Diogo Meyer
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.